---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068011"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T02:04:03.056361+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology

## Summary
- Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.
- Cash increased to $101.6M from $34.6M at year-end 2024, boosted by $76.4M from first tranche of $175M private placement.
- Discontinued SZN-043 for severe alcohol-associated hepatitis due to insufficient Phase 1b benefit; shifted focus to ophthalmology.
- Expects to file IND for lead candidate SZN-8141 in 2026; FDA clearance triggers $98.6M tranche to fund operations.
- Research service revenue $1.0M from TCGFB collaboration; other income $38.0M from non-cash warrant valuation changes.

## SEC filing metadata
- accession: 0000950170-25-068011
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/0000950170-25-068011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/srzn-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068011
- JSON: https://secwatch.observer/filing/0000950170-25-068011.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.